Senate Resolution No. urges the Louisiana Department of Insurance and the Louisiana Department of Health to conduct a comprehensive review and study of the implementation and enforcement of the state's biomarker testing coverage law. This law mandates health insurance coverage for biomarker testing when supported by medical evidence and clinical guidelines, which is crucial for the diagnosis and treatment of serious diseases like cancer. The resolution highlights concerns from various stakeholders regarding access to biomarker testing, including issues related to claims adjudication, delays in testing approval, and the overall impact on patient outcomes.

The resolution calls for a detailed report by February 1, 2027, that will include data on the number of biomarker testing claims, approval and denial rates, reasons for adverse determinations, and the average time from request to testing. It also seeks to identify barriers to patient access and provide recommendations for legislative or regulatory changes to improve compliance and transparency. The study will involve consultations with stakeholders such as healthcare providers, patient advocacy groups, and insurers to ensure a comprehensive understanding of the current landscape of biomarker testing in Louisiana.